{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:03:37Z","timestamp":1793192617370,"version":"4.5.0"},"reference-count":30,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Type 2 diabetes (T2DM) affects millions across the globe, generating a veritable public health issue through quality-of-life-reducing chronic complications, among which urinary tract infections are the most common. A shift in the disease managing paradigm from a glucose-centered view to a concept of cardio-reno-metabolic health has uniquely placed SGLT2 inhibitors as viable medication for the complex management of T2DM and its comorbidities. Some concerns have been raised over the increased likelihood of urinary tract infections (UTIs) associated with SGLT2 inhibitor use. The current study aims to evaluate the risk of developing urinary tract infections if patients with type 2 diabetes take SGLT2 inhibitors and determine those factors which make these patients more prone to develop this undesired complication. Materials and Methods: A cross-sectional, noninterventional evaluation of 328 patients with type 2 diabetes consecutively admitted to the Diabetes Clinic of \u201cPius Brinzeu\u201d County Emergency Hospital in Timisoara, between January and February of 2024, was performed by examining medical charts and running statistical analyses using MedCalc version 22.26.0.0. Results: There was no statistical difference between patients taking SGLT2 inhibitors and those taking other glucose lowering medications when examining the presence of UTIs. Those patients with a higher HbA1c or BMI showed an increased predisposition to contracting UTI. The female gender was also associated with an increased likelihood of UTI. A further evaluation of the sublot of patients taking SGLT2 inhibitors revealed that not only higher BMI or HbA1c could be a predictor for the likelihood of developing UTI, but also a longer duration of T2DM was a predisposing factor. Conclusions: The use of SGLT2 inhibitors did not increase the likelihood of developing a urinary tract infection in this patient population.<\/jats:p>","DOI":"10.3390\/medicina60121974","type":"journal-article","created":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T06:58:58Z","timestamp":1733122738000},"page":"1974","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Safety of SGLT2 Inhibitors and Urinary Tract Infections in Clinical Practice\u2014A Cross-Sectional Study"],"prefix":"10.3390","volume":"60","author":[{"given":"Liana","family":"Iordan","sequence":"first","affiliation":[{"name":"Doctoral School of Medicine and Pharmacy, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"},{"name":"Centre for Molecular Research in Nephrology and Vascular Disease, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlad Florian","family":"Avram","sequence":"additional","affiliation":[{"name":"Centre for Molecular Research in Nephrology and Vascular Disease, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"},{"name":"Department of Diabetes, \u201cPius Brinzeu\u201d Emergency County Hospital, 300723 Timisoara, Romania"},{"name":"Second Department of Internal Medicine, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan","family":"Timar","sequence":"additional","affiliation":[{"name":"Doctoral School of Medicine and Pharmacy, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"},{"name":"Centre for Molecular Research in Nephrology and Vascular Disease, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"},{"name":"Department of Diabetes, \u201cPius Brinzeu\u201d Emergency County Hospital, 300723 Timisoara, Romania"},{"name":"Second Department of Internal Medicine, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Sturza","sequence":"additional","affiliation":[{"name":"Centre for Molecular Research in Nephrology and Vascular Disease, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"},{"name":"Department of Diabetes, \u201cPius Brinzeu\u201d Emergency County Hospital, 300723 Timisoara, Romania"},{"name":"Department of Functional Sciences-Pathophysiology, Centre for Translational Research and Systems Medicine, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Popescu","sequence":"additional","affiliation":[{"name":"Centre for Molecular Research in Nephrology and Vascular Disease, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"},{"name":"Department of Diabetes, \u201cPius Brinzeu\u201d Emergency County Hospital, 300723 Timisoara, Romania"},{"name":"Second Department of Internal Medicine, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2387-5104","authenticated-orcid":false,"given":"Oana","family":"Albai","sequence":"additional","affiliation":[{"name":"Centre for Molecular Research in Nephrology and Vascular Disease, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"},{"name":"Department of Diabetes, \u201cPius Brinzeu\u201d Emergency County Hospital, 300723 Timisoara, Romania"},{"name":"Second Department of Internal Medicine, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0792-9202","authenticated-orcid":false,"given":"Romulus Zorin","family":"Timar","sequence":"additional","affiliation":[{"name":"Doctoral School of Medicine and Pharmacy, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"},{"name":"Centre for Molecular Research in Nephrology and Vascular Disease, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"},{"name":"Department of Diabetes, \u201cPius Brinzeu\u201d Emergency County Hospital, 300723 Timisoara, Romania"},{"name":"Second Department of Internal Medicine, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,1]]},"reference":[{"key":"ref_1","unstructured":"Federation, I.D. (2021). IDF Diabetes Atlas, International Diabetes Federation. [10th ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"100459","DOI":"10.1016\/j.obmed.2022.100459","article-title":"Type 2 diabetes mellitus, its impact on quality of life and how the disease can be managed-a review","volume":"35","author":"Garg","year":"2022","journal-title":"Obes. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1756287219832172","DOI":"10.1177\/1756287219832172","article-title":"An introduction to the epidemiology and burden of urinary tract infections","volume":"11","author":"Medina","year":"2019","journal-title":"Ther. Adv. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Confederat, L.-G., Condurache, M.-I., Alexa, R.-E., and Dragostin, O.-M. (2023). Particularities of Urinary Tract Infections in Diabetic Patients: A Concise Review. Medicina, 59.","DOI":"10.3390\/medicina59101747"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s40265-021-01554-6","article-title":"Evolution of Type 2 Diabetes Management from a Glucocentric Approach to Cardio-Renal Risk Reduction: The New Paradigm of Care","volume":"81","author":"Jacob","year":"2021","journal-title":"Drugs"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Avram, V.F., Merce, A.P., H\u00e2ncu, I.M., B\u0103tr\u00e2n, A.D., Kennedy, G., Rosca, M.G., and Muntean, D.M. (2022). Impairment of Mitochondrial Respiration in Metabolic Diseases: An Overview. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23168852"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2337\/dc15-1585","article-title":"The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the \u03b2-Cell-Centric Classification Schema","volume":"39","author":"Schwartz","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e230005","DOI":"10.1530\/EC-23-0005","article-title":"SGLT2 inhibitors for patients with type 2 diabetes and CKD: A narrative review","volume":"12","author":"Thomas","year":"2023","journal-title":"Endocr. Connect."},{"key":"ref_9","first-page":"394","article-title":"Non-Invasive Assessment of Liver Steatosis and Fibrosis Using Transient Elastography and Controlled Attenuation Parameter in Type 2 Diabetes Patients","volume":"14","author":"Sima","year":"2018","journal-title":"Acta Endocrinol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Braha, A., Albai, A., Timar, R., Diaconu, L., Vasilu\u021b\u0103, L., Cipu, D., Timar, B., and Sima, A. (2020). Factors Associated with the Remission of Type 1 Diastolic Dysfunction after Dapagliflozin Treatment in Patients with Type 2 Diabetes. J. Clin. Med., 9.","DOI":"10.3390\/jcm9113779"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Braha, A., Albai, A., Timar, B., Cipu, D., Vasilu\u021b\u0103, L., Potre, O., and Timar, R. (2021). Predictors of Epicardial Fat Volume Decrease after Dapagliflozin Treatment in Patients with Type 2 Diabetes. Medicina, 58.","DOI":"10.3390\/medicina58010021"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Iordan, L., Gaita, L., Timar, R., Avram, V., Sturza, A., and Timar, B. (2024). The Renoprotective Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i)\u2014A Narrative Review. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25137057"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"20543581231217857","DOI":"10.1177\/20543581231217857","article-title":"Identifying Barriers and Facilitators for Increasing Uptake of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors in British Columbia, Canada, using the Consolidated Framework for Implementation Research","volume":"11","author":"Yi","year":"2024","journal-title":"Can. J. Kidney Health Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4103\/jovr.jovr_279_18","article-title":"Real Life Outcomes vs. Clinical Trial Results","volume":"14","author":"Zarbin","year":"2019","journal-title":"J. Ophthalmic Vis. Res."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Shi, F.-H., Li, H., Shen, L., Zhang, Z., Jiang, Y.-H., Hu, Y.-M., Liu, X.-Y., Gu, Z.-C., Ma, J., and Lin, H.-W. (2019). Appraisal of Non-Cardiovascular Safety for Sodium\u2013Glucose Co-Transporter 2 Inhibitors: A Systematic Review and Meta-Analysis of Placebo-Controlled Randomized Clinical Trials. Front. Pharmacol., 10.","DOI":"10.3389\/fphar.2019.01066"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/ckj\/sfz170","article-title":"The risk for urinary tract infections with sodium-glucose cotransporter 2 inhibitors: No longer a cause of concern?","volume":"13","author":"Sarafidis","year":"2020","journal-title":"Clin. Kidney J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"100082","DOI":"10.1016\/j.deman.2022.100082","article-title":"Incidence and factors associated with genitourinary infections among Type 2 diabetes patients on SGLT2 Inhibitors: A single retrospective cohort study","volume":"7","author":"Caro","year":"2022","journal-title":"Diabetes Epidemiol. Manag."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.diabres.2017.07.004","article-title":"Efficacy and safety of empagliflozin in Japanese patients with type 2 diabetes mellitus: A sub-analysis by body mass index and age of pooled data from three clinical trials","volume":"131","author":"Shiba","year":"2017","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00592-018-1116-0","article-title":"SGLT-2 inhibitors and the risk of infections: A systematic review and meta-analysis of randomized controlled trials","volume":"55","author":"Puckrin","year":"2018","journal-title":"Acta Diabetol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.pcd.2017.06.004","article-title":"Clinical risk factors predicting genital fungal infections with sodium\u2013glucose cotransporter 2 inhibitor treatment: The ABCD nationwide dapagliflozin audit","volume":"12","author":"Thong","year":"2018","journal-title":"Prim. Care Diabetes"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"837","DOI":"10.4103\/ijem.IJEM_159_17","article-title":"Genital Infections with Sodium Glucose Cotransporter-2 Inhibitors: Occurrence and Management in Patients with Type 2 Diabetes Mellitus","volume":"22","author":"Unnikrishnan","year":"2018","journal-title":"Indian J. Endocrinol. Metab."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2337\/db24-941-P","article-title":"941-P: Association of Incidence of Urinary Tract Infections (UTI) and Genitourinary Tract Infections (GTI) with Duration of SGLT2i in Type 2 Diabetes Mellitus Patients\u2014A Pan-India Study","volume":"73","author":"Singh","year":"2024","journal-title":"Diabetes"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.urology.2011.09.040","article-title":"The Impact of Obesity on Urinary Tract Infection Risk","volume":"79","author":"Semins","year":"2012","journal-title":"Urology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41366-021-01035-6","article-title":"Obesity and infectious diseases: Pathophysiology and epidemiology of a double pandemic condition","volume":"46","author":"Pugliese","year":"2022","journal-title":"Int. J. Obes."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Ahmed, A.E., Abdelkarim, S., Zenida, M., Baiti, M.A.H., Alhazmi, A.A.Y., Alfaifi, B.A.H., Majrabi, R.Q.M., Khormi, N.Q.M., Hakami, A.A.A., and Alqaari, R.A.M. (2023). Prevalence and Associated Risk Factors of Urinary Tract Infection among Diabetic Patients: A Cross-Sectional Study. Healthcare, 11.","DOI":"10.3390\/healthcare11060861"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e001238","DOI":"10.1136\/bmjdrc-2020-001238","article-title":"Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation","volume":"8","author":"Andrew","year":"2020","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1007\/s00125-024-06102-x","article-title":"Diabetes and infection: Review of the epidemiology, mechanisms and principles of treatment","volume":"67","author":"Holt","year":"2024","journal-title":"Diabetologia"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Chan, J.C.H., and Chan, M.C.Y. (2023). SGLT2 Inhibitors: The Next Blockbuster Multifaceted Drug?. Medicina, 59.","DOI":"10.3390\/medicina59020388"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/12\/1974\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:44:06Z","timestamp":1760114646000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/12\/1974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,1]]},"references-count":30,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["medicina60121974"],"URL":"https:\/\/doi.org\/10.3390\/medicina60121974","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,1]]}}}